Microvascular/Endothelial Dysfunction Contributes to Post-COVID Syndrome Pathogenesis
By LabMedica International staff writers Posted on 17 May 2022 |

Post-COVID syndrome (PCS) or Long-COVID is an increasingly recognized complication of acute SARS-CoV-2 infection, characterized by persistent fatigue, reduced exercise tolerance chest pain, shortness of breath and cognitive slowing.
Acute COVID-19 is strongly linked with increased risk of thrombosis; a prothrombotic state, quantified by elevated Von Willebrand Factor (VWF) Antigen (Ag):ADAMTS13 ratio, and is associated with severity of acute COVID-19 infection. Acute SARS-CoV-2 infection generates a hypercoagulable state, particularly evident in hospitalized patients.
Hematologist at the University College London Hospitals NHS Foundation Trust (London, UK) and their colleagues assessed 330 patients in an outpatient post-COVID clinic between July 2020 and May 2021. Referral to the post COVID clinic included both patients post hospitalization and referrals from community non-hospitalized cases. The median age of the cohort was 46 years (range 18-88 years). Patients followed up in the clinic varied from 3 to 15 months post proven or presumed COVID-19 infection. The majority (97%) of the patients had symptoms greater than three months following acute COVID-19 infection, of which respiratory symptoms and fatigue were the most common symptoms.
ADAMTS13 activity was measured using FRETS VWF73 assay. Von Willebrand screen (VWF antigen and VWF activity) was measured using standard automated immunoturbimetric assay in a Sysmex CS-2500 analyzer (Sysmex UK, Milton Keynes, UK) with a Siemens kit (VWF:Ag and INNOVANCE VWF activity (Siemens Healthcare Diagnostics, Marburg, Germany), and a clotting based assay using Factor VIII (FVIII) deficient plasma and Dade Actin FS Activated PTT reagent was used to measure FVIII. All analysis was performed on plasma derived from peripheral blood samples collected in sodium citrate tubes, as part of routine assessment in the post COVID clinic which included D-dimer.
The investigators reported that overall, 85 (26%) patients had high factor VIII ranging from 2.1 to 5.1 IU/mL, while 60 (18%) patients had high VWF(Ag) ranging from 1.7-3.3 IU/mL. ADAMTS13 activity ranged from 68.2 to 159.3 IU/dL. The median VWF(Ag):ADAMTS13 ratio was 1.2 (interquartile range [IQR] 0.9-1.5) across the cohort, with an elevated VWF(Ag):ADAMTS13 ratio (≥ 1.5) being observed in 92 patients (28%) across the cohort. Community-managed (83%) and hospitalized patients (16%) had a comparable median VWF(Ag):ADAMTS13 ratio of 1.2. Meanwhile, D-dimer was elevated (>550 µg/L FEU) in 42 (13%) patients.
The authors concluded that their findings suggest an ongoing prothrombotic state in PCS, demonstrated by measurable laboratory and clinical parameters, therefore adding confirmation to the hypothesis of microvascular/endothelial dysfunction in the pathogenesis of PCS. They hypothesized the persistence of a hypercoagulable state which may be associated with endothelial dysfunction and microthrombi in the capillary bed of large muscles, causing a reduction in oxygen capacity during exercise, resulting in anaerobic respiration and fatigue. The study was published on May 11, 2022 in the journal Blood Advances.
Related Links:
University College London Hospitals NHS Foundation Trust
Sysmex UK
Siemens Healthcare Diagnostics
Latest Hematology News
- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
- WBC Count Could Predict Severity of COVID-19 Symptoms
- New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
- Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
- POC Hemostasis System Could Help Prevent Maternal Deaths
- New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape
- Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals
- Non-Invasive Test Solution Determines Fetal RhD Status from Maternal Plasma
- First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC
- Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results
- Newly Discovered Blood Group System to Help Identify and Treat Rare Patients
- Blood Platelet Score Detects Previously Unmeasured Risk of Heart Attack and Stroke
- Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere
- New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Channels
Clinical Chemistry
view channel
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
Children are experiencing metabolic problems at increasingly younger ages, placing them at higher risk for serious health issues later in life. There is a growing need to identify this risk from birth... Read more
Spinal Fluid Biomarker for Parkinson’s Disease Offers Early and Accurate Diagnosis
Parkinson’s disease is a neurodegenerative condition typically diagnosed at an advanced stage based on clinical symptoms, primarily motor disorders. However, by this time, the brain has already undergone... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more